In non-small-cell lung cancer (NSCLC), pathogenic STK11 mutations are associated with poor prognosis in the KRAS-mutated subtype and have emerged as predictive biomarkers for primary resistance to ICIs [19, 20]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.